News | April 09, 2026
Insmed’s Brensocatib fails to hit endpoints in hidradenitis suppurativa study
The results were consistent across both the 10 mg and 40 mg treatment arms
The results were consistent across both the 10 mg and 40 mg treatment arms
Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
The trial also demonstrated significant improvements across multiple secondary endpoints
Safety was equally impressive. ENV-294 was well tolerated
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Subscribe To Our Newsletter & Stay Updated
